Edward Aloysius Sullivan Jr. - 31 Dec 2022 Form 5 Insider Report for Comera Life Sciences Holdings, Inc. (CMRA)

Role
Director
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Issuer symbol
CMRA
Transactions as of
31 Dec 2022
Transactions value $
$0
Form type
5
Filing time
14 Feb 2023, 17:04:54
Previous filing
20 May 2022
Next filing
14 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMRA Stock Option (Right to Buy) Award +45K 45K 19 May 2022 Common Stock 45K $0.59 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option vest in 48 equal monthly installments beginning on September 16, 2021.
F2 This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company.